Griffiths, GO;
Cowan, R;
Grigor, KM;
Uscinska, BM;
Sydes, MR;
Russell, M;
(2019)
BA08: An open-label, single-arm, non-randomised, phase 2 trial of cisplatin, methotrexate and vinblastine (CMV) for pure squamous cell cancer of the urinary tract.
PLoS One
, 14
(1)
, Article e0210785. 10.1371/journal.pone.0210785.
Preview |
Text
Sydes_BA08. An open-label, single-arm, non-randomised, phase 2 trial of cisplatin, methotrexate and vinblastine (CMV)_VoR.pdf - Published Version Download (622kB) | Preview |
Abstract
BACKGROUND: Pure squamous cell carcinoma (SCC) of the urinary tract is rare in the UK and has a poor prognosis compared with transitional cell carcinoma (TCC). Cisplatin based chemotherapy has been shown to be effective in TCC. METHODS: Patients with T3-T4, pelvic relapsed, nodal or metastatic SCC of the urinary tract were recruited into an open-label, single-arm, non-randomised, phase 2 trial evaluating the activity and safety of cisplatin, methotrexate and vinblastine (CMV) chemotherapy. CMV was given as three 21-day cycles of methotrexate 30mg/m² (day 1 & 8), vinblastine 4mg/m² (day 1 & 8) and cisplatin 100mg/m² (day 2). RESULTS: 38 patients were recruited. Overall response was 39% (95% CI 24%, 55%)–13% CR and 26% PR. Median OS was 7.8 months (95% CI 3.4, 12.6) with 39% 1-year survival. Toxicity was acceptable. CONCLUSION: CMV is well tolerated and active in patients with pure SCC of the urinary tract.
| Type: | Article |
|---|---|
| Title: | BA08: An open-label, single-arm, non-randomised, phase 2 trial of cisplatin, methotrexate and vinblastine (CMV) for pure squamous cell cancer of the urinary tract |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.1371/journal.pone.0210785 |
| Publisher version: | https://doi.org/10.1371/journal.pone.0210785 |
| Language: | English |
| Additional information: | © 2019 Griffiths et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). |
| Keywords: | Squamous cell carcinomas, Cancer chemotherapy, Renal system, Toxicity, Cancer treatment, Bladder, Methotrexate, Lesions |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > Inst of Clinical Trials and Methodology UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > Inst of Clinical Trials and Methodology > MRC Clinical Trials Unit at UCL |
| URI: | https://discovery.ucl.ac.uk/id/eprint/10066179 |
Archive Staff Only
 |
View Item |
